+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Latin American Pharmaceutical Market Set To Grow To $126bn By 2022

08 August 2018
Pharma

Visiongain has launched a new pharma report Latin American Pharmaceutical Market Outlook 2018-2028: Brazil, Mexico, Venezuela, Argentina, Colombia, Chile, Rest of Latin America, Generics, OTC, Biosimilars, Originator Drugs

The Latin American pharmaceutical market accounts for 8% of the global pharmaceutical industry, and is one of its fastest growing markets. Macroeconomic conditions are hampering growth in the short term, but long-term growth is expected at high rates to 2028 and beyond. Many multinational companies have successfully gained entry to this market and are making large gains, but it remains a challenging environment for new entrants. The Latin American market requires strong local knowledge, as there are large differences between its constituent nations.

The lead analyst of this report said “The Latin American pharmaceutical market will continue to grow at a much higher rate than other, more mature markets for the next ten years. The reasons behind this growth will shift from expanding coverage to increasing incidence of diseases as the nations of Latin America develop economically. Governments across the region are looking to increase access to health care and an ageing population coupled with rises in the incidence of chronic diseases are driving demand.

Competition is high from both foreign and domestic companies, and national regulations can make investment difficult. Nevertheless, success in the Latin American pharmaceutical market is crucial for pharmaceutical companies seeking to maintain growth rates as developed markets stagnate.”

Leading companies featured in the report include Pfizer Inc., Bayer AG, Sanofi S.A, Novartis AG
And EMS SA.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read